DNA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -63.95% compared to Ginkgo Bioworks Holdings's net margin of --. Ginkgo Bioworks Holdings's return on equity of -65.54% beat Perspective Therapeutics's return on equity of --.

Ginkgo Bioworks Holdings has a consensus price target of $37.00, signalling downside risk potential of -12.49%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Ginkgo Bioworks Holdings, analysts believe Perspective Therapeutics is more attractive than Ginkgo Bioworks Holdings.

Ginkgo Bioworks Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Ginkgo Bioworks Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings quarterly revenues are $88.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Ginkgo Bioworks Holdings's net income of -$56.4M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Ginkgo Bioworks Holdings's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings is 2.19x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Clearside Biomedical has a net margin of -63.95% compared to Ginkgo Bioworks Holdings's net margin of -740.66%. Ginkgo Bioworks Holdings's return on equity of -65.54% beat Clearside Biomedical's return on equity of --.

Ginkgo Bioworks Holdings has a consensus price target of $37.00, signalling downside risk potential of -12.49%. On the other hand Clearside Biomedical has an analysts' consensus of -- which suggests that it could grow by 545.86%. Given that Clearside Biomedical has higher upside potential than Ginkgo Bioworks Holdings, analysts believe Clearside Biomedical is more attractive than Ginkgo Bioworks Holdings.

Ginkgo Bioworks Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Clearside Biomedical has a beta of 2.292, suggesting its more volatile than the S&P 500 by 129.225%.

Ginkgo Bioworks Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearside Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings pays -- of its earnings as a dividend. Clearside Biomedical pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings quarterly revenues are $88.2M, which are larger than Clearside Biomedical quarterly revenues of $1M. Ginkgo Bioworks Holdings's net income of -$56.4M is lower than Clearside Biomedical's net income of -$7.7M. Notably, Ginkgo Bioworks Holdings's price-to-earnings ratio is -- while Clearside Biomedical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings is 2.19x versus 8.49x for Clearside Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

Corvus Pharmaceuticals has a net margin of -63.95% compared to Ginkgo Bioworks Holdings's net margin of --. Ginkgo Bioworks Holdings's return on equity of -65.54% beat Corvus Pharmaceuticals's return on equity of --.

Ginkgo Bioworks Holdings has a consensus price target of $37.00, signalling downside risk potential of -12.49%. On the other hand Corvus Pharmaceuticals has an analysts' consensus of $15.75 which suggests that it could grow by 221.43%. Given that Corvus Pharmaceuticals has higher upside potential than Ginkgo Bioworks Holdings, analysts believe Corvus Pharmaceuticals is more attractive than Ginkgo Bioworks Holdings.

Ginkgo Bioworks Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corvus Pharmaceuticals has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.936%.

Ginkgo Bioworks Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings pays -- of its earnings as a dividend. Corvus Pharmaceuticals pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings quarterly revenues are $88.2M, which are larger than Corvus Pharmaceuticals quarterly revenues of --. Ginkgo Bioworks Holdings's net income of -$56.4M is lower than Corvus Pharmaceuticals's net income of -$40.2M. Notably, Ginkgo Bioworks Holdings's price-to-earnings ratio is -- while Corvus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings is 2.19x versus -- for Corvus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of -63.95% compared to Ginkgo Bioworks Holdings's net margin of -3703.49%. Ginkgo Bioworks Holdings's return on equity of -65.54% beat Lexicon Pharmaceuticals's return on equity of -115.11%.

Ginkgo Bioworks Holdings has a consensus price target of $37.00, signalling downside risk potential of -12.49%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $3.60 which suggests that it could grow by 375.06%. Given that Lexicon Pharmaceuticals has higher upside potential than Ginkgo Bioworks Holdings, analysts believe Lexicon Pharmaceuticals is more attractive than Ginkgo Bioworks Holdings.

Ginkgo Bioworks Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.862%.

Ginkgo Bioworks Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ginkgo Bioworks Holdings pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Ginkgo Bioworks Holdings quarterly revenues are $88.2M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.8M. Ginkgo Bioworks Holdings's net income of -$56.4M is higher than Lexicon Pharmaceuticals's net income of -$64.8M. Notably, Ginkgo Bioworks Holdings's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ginkgo Bioworks Holdings is 2.19x versus 42.13x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.